Brind.
  1. Alto Neuroscience is leveraging Trump-era tariffs and AI trends to advance its drug candidate ALTO-203 for Major Depressive Disorder (MDD).

Amit Etkin was appointed Founder and CEO of Alto Neuroscience on August 14, 2025.

3 reports, 1 independent Updated Aug 14
Gone quiet
Reports
3
Developments
3
Repetition
0%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Amit Etkin was appointed Founder and CEO of Alto Neuroscience on August 14, 2025.

Who's involved

What this event is mainly about
Alto Neuroscience (United States)Amit Etkin

How it developed

Newest first. Tap a step to see who reported it.
  1. Amit Etkin appointed as Founder and CEO of Alto Neuroscience.1 source
  2. Raymond Sanchez joined Alto Neuroscience's Board of Directors alongside Etkin's CEO appointment.1 source
  3. Alto Neuroscience's founder Amit Etkin confirmed, and the company received FDA clearance for a clinical biomarker.

Keep exploring

Part of

Alto Neuroscience is leveraging Trump-era tariffs and AI trends to advance its drug candidate ALTO-203 for Major Depressive Disorder (MDD). All 1 developments

The entities involved

Coverage

Newest first; wire copies grouped
  • Business WireAlto Neuroscience Reports Second Quarter 2025 Financial Results and Recent Business Highlights – Acquisition of potentially best-in-class dopamine agonist combination product candidates, including AL
  • Business WireAlto Neuroscience Appoints Biotech Industry Veteran, Raymond Sanchez, M.D., to Its Board of Directors MOUNTAIN VIEW, Calif., August 13, 2025--(BUSINESS WIRE)--Alto Neuroscience, Inc. ("Alto") (NYSE:
  • Unknown outlet